Ionis Pharmaceuticals Inc (NAS:IONS)
$ 38.8 -0.28 (-0.72%) Market Cap: 5.66 Bil Enterprise Value: 4.94 Bil PE Ratio: 0 PB Ratio: 19.11 GF Score: 74/100

Ionis Pharmaceuticals Inc at Stifel Healthcare Conference Transcript

Nov 15, 2022 / 04:30PM GMT
Release Date Price: $43.52 (-1.18%)
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

So I'm happy to be monitoring the discussion with the Ionis team. We'll do mostly Q&A. And if anyone in the audience has questions, please raise your hands. And hopefully, more folks will filter in throughout. But maybe we can start, Eric or Onaiza, do you want to give just kind of an overview, high level of the R&D pipeline, some of the key later-stage assets and the cadence of readouts over the next year or so?

Questions & Answers

Eric E. Swayze
Ionis Pharmaceuticals, Inc. - EVP of Research

Yes. I'll start. We've got a pretty full pipeline, as I think most people know. And we had a pretty eventful year so far to date with lots of news and lots of advancement of the pipeline.

So I'm going to start with eplontersen. We had a positive interim Phase III readout for eplontersen in the polyneuropathy space, partnered with AstraZeneca, and we plan to file to the FDA for approval later this year based

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot